New eye injection could mean fewer doctor visits for wet AMD patients
Disease control
Not yet recruiting
This study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce t…
Phase: PHASE2 • Sponsor: AiViva BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC